| 吴伦涛,丁永锋,徐 农.外周血NLR和PLR在接受免疫治疗肿瘤患者中的预后价值[J].中国肿瘤,2022,31(1):67-74. |
| 外周血NLR和PLR在接受免疫治疗肿瘤患者中的预后价值 |
| Predictive Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Advanced Cancer Patients Treated with Immunotherapy |
| 中文关键词 修订日期：2021-11-22 |
| DOI：10.11735/j.issn.1004-0242.2022.01.A008 |
|
 |
| 中文关键词: 恶性肿瘤 外周血 中性粒细胞与淋巴细胞比值 血小板与淋巴细胞比值 免疫治疗 预后 |
| 英文关键词:malignant tumor peripheral blood neutrophil to lymphocyte ratio platelet to lymphocyte ratio immunotherapy prognosis |
| 基金项目: |
|
| 摘要点击次数: 1107 |
| 全文下载次数: 183 |
| 中文摘要: |
| 摘 要：持续的全身慢性炎症在恶性肿瘤的发生、进展、转移过程中起着重要作用。外周血中性粒细胞与淋巴细胞比值（neutrophil-to-lymphocyte ratio，NLR）和血小板与淋巴细胞比值（platelet-to-lymphocyte ratio，PLR）与多种恶性肿瘤如肺癌、恶性黑色素瘤、消化道恶性肿瘤、肝癌等免疫治疗的预后具有显著相关性，同时NLR和PLR检测具有价格低、创伤小、易获得、可重复性高的特点。研究表明，较高的基线或用药后NLR和PLR水平与患者对免疫治疗的反应、预后均呈负相关，且患者出现免疫治疗抵抗、肿瘤进展或死亡的风险更高，预期无进展生存期（progression free survival，PFS）、总生存期（overall survival，OS）相较于低NLR和低PLR患者更短。该文就NLR和PLR与多种接受免疫治疗的恶性肿瘤患者预后的相关研究作一综述，为寻找针对免疫治疗的最佳预后指标、早期筛选出免疫治疗潜在获益患者以及预测他们的治疗结局提供依据。 |
| 英文摘要: |
| Abstract： Persistent systemic chronic inflammation plays an important role in occurrence， progression， and metastasis of malignant tumors. Peripheral blood neutrophil-to-lymphocyte ratio(NLR) and platelet-to-lymphocyte ratio(PLR) have been found to have significant correlation with the prognosis of a variety of malignant tumors， such as lung cancer， malignant melanoma， gastrointestinal cancers， liver cancer， etc. The tests for NLR and PLR are inexpensive， non-invasive， readily available and reproducible. Studies have shown that the baseline and post-treatment NLR and PLR levels are correlated with the response to immunotherapy and prognosis of patients. Patients with higher NLR and PLR are likely to developed immunotherapy resistance， tumor progression or death; they have shorter progression free survival(PFS) and overall survival(OS). This article reviews the recent researches on the relationship between NLR/PLR and the prognosis of cancer patients， their values in predicting outcomes of advanced cancer patients receiving immunotherapy. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |